<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04221516</url>
  </required_header>
  <id_info>
    <org_study_id>2018CR021</org_study_id>
    <nct_id>NCT04221516</nct_id>
  </id_info>
  <brief_title>Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma</brief_title>
  <official_title>Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma: A Phase 2 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to see how well the experimental drug&#xD;
      camrelizumab(SHR-1210) works in people with oligometastatic NPC who have already had locally&#xD;
      radiotherapy for their disease. All patients will receive 200 mg of camrelizumab&#xD;
      intravenously on Day 1 of each 21-day cycle. Patients will receive the study drug for up to&#xD;
      18 cycles.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Time to progression or death from initiation of Camrelizumab</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Camrelizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Camrelizumab 200mg every 21 days (3 weeks), from 4 to 12 weeks after the completion of radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>Camrelizumab 200mg every 21 days (3 weeks), from 4 to 12 weeks after the completion of radiotherapy.</description>
    <arm_group_label>Camrelizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically confirmed non-keratinizing (according to World Health&#xD;
             Organization (WHO) histologically type).&#xD;
&#xD;
          -  Patients with oligometastatic NPC (defined as ≤5 metastases, ≤2 organs), without local&#xD;
             recurrence of nasopharynx.&#xD;
&#xD;
          -  Completion of radiotherapy 4-12 weeks prior to enrollment. At list one cycle of&#xD;
             adjuvant platinum-based chemotherapy.&#xD;
&#xD;
          -  Satisfactory performance status: Karnofsky scale (KPS) &gt; 70.&#xD;
&#xD;
          -  Adequate marrow: leucocyte count ≥4000/μL, hemoglobin ≥90g/L and platelet count&#xD;
             ≥100000/μL.&#xD;
&#xD;
          -  Normal liver function test: Alanine Aminotransferase (ALT)、Aspartate Aminotransferase&#xD;
             (AST) &lt;1.5×upper limit of normal (ULN) concomitant with alkaline phosphatase (ALP)&#xD;
             ≤2.5×ULN, and bilirubin ≤ULN.&#xD;
&#xD;
          -  Adequate renal function: creatinine clearance ≥50 ml/min.&#xD;
&#xD;
          -  Expected lifetime over 3 months&#xD;
&#xD;
          -  Patients must be informed of the investigational nature of this study and give written&#xD;
             informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous history of autoimmune disease or unstable autoimmune disease.&#xD;
&#xD;
          -  Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in&#xD;
             situ cervical cancer.&#xD;
&#xD;
          -  Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic&#xD;
             T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other&#xD;
             antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).&#xD;
&#xD;
          -  Active autoimmune disease requiring systemic treatment within the past 3 months or a&#xD;
             documented history of clinically severe autoimmune disease, or a syndrome that&#xD;
             requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or&#xD;
             resolved childhood asthma/atopy are an exception to this rule. Subjects that require&#xD;
             intermittent use of bronchodilators or local steroid injections are not excluded from&#xD;
             the study. Subjects with hypothyroidism stable on hormone replacement or Sjorgen's&#xD;
             syndrome are not excluded from the study.&#xD;
&#xD;
          -  Any severe intercurrent disease, which may bring unacceptable risk or affect the&#xD;
             compliance of the trial, for example, unstable cardiac disease requiring treatment,&#xD;
             renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose&#xD;
             &gt;1.5×ULN), and emotional disturbance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian Guan, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanfang Hospital of Southern Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jian Guan, Ph.D.</last_name>
    <phone>+86-13632102247</phone>
    <email>51643930@qq.com</email>
  </overall_contact>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>January 6, 2020</study_first_submitted>
  <study_first_submitted_qc>January 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2020</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

